The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.
World J Surg Oncol
; 19(1): 298, 2021 Oct 14.
Article
en En
| MEDLINE
| ID: mdl-34645484
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Monoclonales Humanizados
/
Neoplasias Pulmonares
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Idioma:
En
Revista:
World J Surg Oncol
Año:
2021
Tipo del documento:
Article